Articles

Men's Grooming Demand On The Rise In Latin America

Consumer & Retail / Latin America / Tue 19 Mar, 2024

Key View: While we have noted the rise of men’s grooming demand globally, in the Latin America region we see growth coming from a more nascent base. Lower levels of disposable incomes and cultural norms have stunted growth in previous decades; however, premiumisation in hair, skin and beard segments are rapidly growing. Imports remain a key

Read More

Chile’s Gabriel Boric Will Remain Unpopular Despite Some Wins

Country Risk / Chile / Tue 19 Mar, 2024

Key View

  • Chile’s left-wing president, Gabriel Boric, will remain unpopular despite the rejection of a right-wing constitution by the Chilean public in late 2023, and a likely passage of a modified pension bill. 
  • The January passage of a pension reform plan through the chamber of deputies was a rare win for Boric, whose legislative agenda
Read More

Oman To Set New Tourism Growth Trajectory Amid Robust Arrivals Growth

Tourism / Oman / Tue 19 Mar, 2024

Key View: We forecast Oman’s arrivals to grow by 24.7% y-o-y in 2024 to a total of 5.3mn. The 2024 arrivals levels will be a new high, building on the most recent historic peak in 2023. Arrivals will continue to expand over the remainder of our medium-term forecast period (2024-2028) to reach a projected 10.8mn by 2028. Our forecasted arrivals

Read More

Sri Lanka: Recovery Will Strengthen In 2024

Country Risk / Sri Lanka / Tue 19 Mar, 2024

Key View

  • As we had expected, Sri Lankan growth picked up in Q4 2023, and we think that the country’s recovery will gain ground in 2024. We have penciled in GDP growth of 3.5% for the year as a whole.  
  • Provided, as we expect, that inflation remains subdued and that the tourism sector continues to recover, risks are now probably weighted to
Read More

Parkinson’s Disease: Approval Of Disease Modifying Therapies Will Be Key To Better Treatment Outcomes

Pharmaceuticals / United States / Mon 18 Mar, 2024

Key View 

  • A lack of current effective treatment is driving research into disease modifying therapies (DMTs) for Parkinson’s disease (PD). 
  • We expect Alpha Synuclein (ASN) Inhibitors will be the first form of DMT for PD to receive FDA approval. 
  • Drugs which engage neuronal rescue pathways, like GLP-1 agonists, have also shown promise in
Read More
Download Indicator Summary
 

Thank you. Your download link will be emailed to you shortly.

Download Now
 

Thank you. Your download link will be emailed to you shortly.

Download Now
 

Thank you. Your download link will be emailed to you shortly.

Clearbit Form
 

Thank you. Your download link will be emailed to you shortly.